EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival outcomes and prognostic value of nutritional and inflammatory markers in third-line treatment of metastatic pancreatic cancer

Júlia Vidulin, Dalibor Ondruš, Śtefan Pöršök, Melinda Kráčalíková, Vanda Ušáková, Kristián Šuták, Michaela Miškovičová, Marína Kizeková, Maroš Fremal, Jana Pisáková, Ivan Kecskés, Jaroslava Lešková und 1 weitere

Frontiers in Oncology · 24.03.2026 · 16

DOI: 10.3389/fonc.2026.1713376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 24.03.2026. Verfasst von Júlia Vidulin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Faculty Hospital, Trenčín, Slovakia. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is one of the most aggressive malignancies with a very poor prognosis. Currently, there is no standardized therapeutic approach for third-line systemic treatment. The aim of this retrospective/prospective study was to evaluate survival outcomes in patients treated in the third-line setting and to analyze the impact of nutritional and inflammatory biomarkers on overall survival (OS) and progression-free survival (PFS).

Methods

The analysis retrospectively and prospectively included 95 patients with mPDAC treated with third-line systemic therapy. Data were collected from the Slovak Pancreas Registry. Data were collected from 13 hospitals. Baseline chemotherapy regimens, ECOG, nutritional, and inflammatory parameters were recorded and used to calculate prognostic scores (PNI, CRP, NLR, SII, SIRI, GPS). Their association with OS and PFS was analyzed using the log-rank test and Kaplan-Meier survival analysis.

Results

The most frequently used regimen was FOLFOX/CAPOX (56 patients), followed by nanoliposomal irinotecan (nal-IRI, 24 patients) and capecitabine (11 patients). The median OS was 5.55 months and the median PFS was 3.29 months. A PNI > 40.5 was significantly associated with longer OS (6.34 vs. 3.32 months, p = 0.001) and PFS (3.71 vs. 2.76 months, p = 0.009). Lower GPS scores were significantly associated with improved OS ( p = 0.006) and PFS ( p = 0.027). Other inflammatory markers (NLR, SIRI, SII, CRP) did not show a statistically significant impact on OS or PFS.

Conclusion

Third-line systemic therapy may offer clinical benefit in selected mPDAC patients, particularly in those with favorable nutritional-inflammatory profiles. The Prognostic Nutritional Index (PNI) and Glasgow Prognostic Score (GPS) appear to be potentially useful tools for identifying candidates suitable for further systemic treatment. However, further prospective studies are needed to confirm these findings.

Schlagwörter

Stichwörter der Autor:innen

C-reactive protein (CRP)glasgow prognostic score (GPS)inflammatory biomarkersmetastatic pancreatic cancerneutrophil-to-lymphocyte ratio (NLR)nutritional biomarkersprognostic nutritional index (PNI)systemic inflammation response index (SIRI)

Autor:innen und Institutionen

  • Department of Oncology, Faculty Hospital, Trenčín, Slovakia.
  • 1st Department of Oncology, Faculty of Medicine, Comenius University in Bratislava and St. Elisabeth Cancer Institute, Bratislava, Slovakia.
  • 2nd Department of Oncology, Faculty of Medicine, Comenius University in Bratislava and National Cancer Institute, Bratislava, Slovakia.
  • Department of Oncology, Faculty Hospital, Trnava, Slovakia.
  • Department of Oncology, Faculty Hospital, Nitra, Slovakia.
  • Department of Oncology, F. D. Roosevelt University Hospital, Banská Bystrica, Slovakia.

Zitieren

APA

Vidulin, J., Ondruš, D., Pöršök, Ś., Kráčalíková, M., Ušáková, V., Šuták, K., Miškovičová, M., Kizeková, M., Fremal, M., Pisáková, J., Kecskés, I., Lešková, J., & Bystrický, B. (2026). Survival outcomes and prognostic value of nutritional and inflammatory markers in third-line treatment of metastatic pancreatic cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1713376

Vancouver

Vidulin J, Ondruš D, Pöršök Ś, Kráčalíková M, Ušáková V, Šuták K, et al. Survival outcomes and prognostic value of nutritional and inflammatory markers in third-line treatment of metastatic pancreatic cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1713376

BibTeX
@article{Vidulin2026,
  author = {Vidulin, Júlia and Ondruš, Dalibor and Pöršök, Śtefan and Kráčalíková, Melinda and Ušáková, Vanda and Šuták, Kristián and Miškovičová, Michaela and Kizeková, Marína and Fremal, Maroš and Pisáková, Jana and Kecskés, Ivan and Lešková, Jaroslava and Bystrický, Branislav},
  title = {Survival outcomes and prognostic value of nutritional and inflammatory markers in third-line treatment of metastatic pancreatic cancer},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1713376}
}
Kostenlos starten →